EUCTR2010-023081-52-NL
Active, not recruiting
Not Applicable
A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. - ENGOT-EN2-DGCG
Danish Gynaecological Cancer Group0 sites678 target enrollmentSeptember 28, 2015
Conditionsode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 18.0Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ode-negative stage I-II intermediate or high risk endometrial cancer
- Sponsor
- Danish Gynaecological Cancer Group
- Enrollment
- 678
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Only node\-negative patients are eligible: Histological confirmed endometrial carcinoma with no macroscopic remaining tumour after
- •primary surgery and lymph\-node negative disease, with one of the following postoperative FIGO 2009 stage and grade:
- •a.Stage I grade 3 endometrioid adenocarcinoma
- •b.Stage II endometrioid adenocarcinoma
- •c.Stage I and II type 2 histology (clear cell, serous, or squamous cell
- •carci\-noma, or undifferentiated carcinoma)
- •2\. Patients with prior therapy:
- •a. Patients have undergone hysterectomy (total abdominal hysterectomy (TAH), radical hysterectomy, laparoscopic or robotic hysterectomy) and
- •\& bilateral salpingo\-oopherectomy (BSO) (or RH) and\+ pelvic lymphadenectomy (LNE) within the past 10 weeks.
- •b. LNE: minimum 12 pelvic nodes (6 from each side) should be removed. Para\-aortic LNE is optional
Exclusion Criteria
- •Target Disease Exceptions
- •1\. Carcinosarcoma, Sarcomas or small cell carcinoma with
- •neuroendocrine differentiation.
- •Prohibited Treatments and/or Therapies
- •2\. External Beam Radiotherapy
- •3\. Concurrent cancer therapy
- •4\. Concurrent treatment with an anticancer investigational agent or
- •participation in anotheranticancer clinical trial
- •Other exclusion criteria
- •5\. Previous or concurrent malignant disease except for curatively treated
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Postoperative chemotherapy or no treatment in endometrial cancerEndometrial cancerMedDRA version: 18.1Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023081-52-FIDanish Gynaecological Cancer Group678
Active, not recruiting
Not Applicable
A phase III clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.ode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 15.1Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023081-52-PTDanish Gynaecological Cancer Group678
Active, not recruiting
Not Applicable
A phase III clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.ode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 16.0Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023081-52-ESDanish Gynaecological Cancer Group678
Recruiting
Phase 3
A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.endometrial canceruterine cancer10038594NL-OMON41312Danish Gynecological Cancer Group12
Active, not recruiting
Not Applicable
A phase III clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.ode-negative stage I-II intermediate or high risk endometrial cancerMedDRA version: 17.0Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023081-52-ITDanish Gynaecological Cancer Group678